We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Molecular Devices Introduces Aequorin Option for FLIPR Tetra® Screening System
Product News

Molecular Devices Introduces Aequorin Option for FLIPR Tetra® Screening System

Molecular Devices Introduces Aequorin Option for FLIPR Tetra® Screening System
Product News

Molecular Devices Introduces Aequorin Option for FLIPR Tetra® Screening System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Molecular Devices Introduces Aequorin Option for FLIPR Tetra® Screening System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Molecular Devices has announced an aequorin option for its FLIPR Tetra® fluorometric imaging plate reader. This addition to the FLIPR Tetra system includes designed camera that can detect both fluorescence and aequorin luminescence - and a new cell suspension option.

Both the camera and cell suspension option were optimized on FLIPR Tetra to enable researchers to expand their calcium mobilization assays to include aequorin luminescence measurements.

FLIPR Tetra system is a single camera to monitor aequorin luminescence and fluorescence-based calcium and membrane potential assays. Sensitivity can be adjusted to the appropriate assay signal window to detect dim aequorin cell lines while maintaining the ability to screen using traditional fluorescence methods.

The aequorin option can enable cell suspension assays, thereby minimizing cell preparation time. The cell suspension feature also increases throughput by delivering cells in up to 1536 wells using proven FLIPR® pipettor technology. FLIPR Tetra optics (LEDs, emission filters, and standard camera) and automation capabilities are available for site-specific laboratory configuration.

"With the addition of the aequorin option for FLIPR Tetra, we can offer FLIPR® users the added benefits of reduced assay costs and fewer technical requirements associated with running aequorin applications," said Andy Boorn, President of MDS Analytical Technologies.

"We are excited to provide the industry with another innovative screening solution that will enable higher throughput and lower-cost options for drug discovery," Boorn added.

Advertisement